Breast Cancer Cell Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 1 of 3: Cell count and normalized growth rate inhibition values. - Dataset (ID:20256)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Replicate | Seeding Density | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Lapatinib | 0.0016596 | uM | 9 | 312.50 | 200.50 | 337.00 | 286.50 | 1.1763 | 1.7413 |
| SK-BR-3 | 17-AAG | 0.01 | uM | 9 | 312.50 | 200.50 | 276.00 | 286.50 | 0.9634 | 0.8601 |
| SK-BR-3 | Lapatinib | 0.031623 | uM | 9 | 312.50 | 200.50 | 321.00 | 286.50 | 1.1204 | 1.4942 |
| SK-BR-3 | Lapatinib | 0.0033113 | uM | 9 | 312.50 | 200.50 | 488.00 | 286.50 | 1.7033 | 4.6261 |
| SK-BR-3 | 17-AAG | 0.1 | uM | 9 | 312.50 | 200.50 | 147.00 | 286.50 | 0.5131 | -0.4527 |
| SK-BR-3 | Linsitinib | 0.0033113 | uM | 9 | 312.50 | 200.50 | 394.00 | 286.50 | 1.3752 | 2.7132 |
| SK-BR-3 | Linsitinib | 3.1623 | uM | 9 | 312.50 | 200.50 | 327.00 | 286.50 | 1.1414 | 1.5855 |
| SK-BR-3 | Erlotinib | 0.0033113 | uM | 9 | 312.50 | 200.50 | 332.00 | 286.50 | 1.1588 | 1.6628 |
| SK-BR-3 | Lapatinib | 1 | uM | 9 | 312.50 | 200.50 | 138.00 | 286.50 | 0.4817 | -0.5159 |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 226.00 | 286.50 | 0.7888 | 0.2618 | |
| SK-BR-3 | 0 | uM | 9 | 625.00 | 414.82 | 721.00 | 799.25 | 0.9021 | 0.7937 | |
| SK-BR-3 | Linsitinib | 0.1 | uM | 9 | 625.00 | 414.82 | 756.00 | 799.25 | 0.9459 | 0.8858 |
| SK-BR-3 | Lapatinib | 3.1623 | uM | 9 | 625.00 | 414.82 | 375.00 | 799.25 | 0.4692 | -0.1012 |
| SK-BR-3 | Linsitinib | 10 | uM | 9 | 625.00 | 414.82 | 641.00 | 799.25 | 0.8020 | 0.5840 |
| SK-BR-3 | Erlotinib | 0.1 | uM | 9 | 625.00 | 414.82 | 1078.00 | 799.25 | 1.3488 | 1.7438 |
| SK-BR-3 | Erlotinib | 19.9526 | uM | 9 | 625.00 | 414.82 | 806.00 | 799.25 | 1.0084 | 1.0179 |
| SK-BR-3 | Erlotinib | 1 | uM | 9 | 625.00 | 414.82 | 798.00 | 799.25 | 0.9984 | 0.9967 |
| SK-BR-3 | 17-AAG | 0.0031623 | uM | 9 | 625.00 | 414.82 | 688.00 | 799.25 | 0.8608 | 0.7070 |
| SK-BR-3 | 0 | uM | 9 | 625.00 | 414.82 | 1013.00 | 799.25 | 1.2674 | 1.5693 | |
| SK-BR-3 | Linsitinib | 1 | uM | 9 | 625.00 | 414.82 | 1030.00 | 799.25 | 1.2887 | 1.6149 |
| SK-BR-3 | Erlotinib | 0.031623 | uM | 9 | 625.00 | 414.82 | 1052.00 | 799.25 | 1.3162 | 1.6739 |
| SK-BR-3 | Lapatinib | 0.31623 | uM | 9 | 625.00 | 414.82 | 475.00 | 799.25 | 0.5943 | 0.1539 |
| SK-BR-3 | 17-AAG | 0.0001 | uM | 9 | 625.00 | 414.82 | 843.00 | 799.25 | 1.0547 | 1.1159 |
| SK-BR-3 | 0 | uM | 9 | 625.00 | 414.82 | 741.00 | 799.25 | 0.9271 | 0.8463 | |
| SK-BR-3 | 17-AAG | 0.000302 | uM | 9 | 625.00 | 414.82 | 954.00 | 799.25 | 1.1936 | 1.4114 |